Fibroblast growth factor 21 levels and liver inflammatory biomarkers in obese subjects after weight loss - PubMed (original) (raw)

Fibroblast growth factor 21 levels and liver inflammatory biomarkers in obese subjects after weight loss

Irene Cantero et al. Arch Med Sci. 2021.

Abstract

Introduction: Previous studies have hypothesized fibroblast growth factor 21 (FGF-21) as a potential biomarker of the inflammation associated with liver diseases, which is also receiving considerable attention for its potential application concerning the management of obesity and co-morbidities. This study aimed to analyze the response of FGF-21 after a weight loss intervention and the relationships with other putative inflammatory liver biomarkers.

Material and methods: Sixty-six obese participants from the RESMENA study were evaluated at baseline and following a 6-month energy restriction treatment. Anthropometric, body composition by DXA, routine laboratory measurements, which included transaminases and γ-glutamyl transferase (GGT) were analyzed by standardized methods. Moreover, FGF-21, M30 fragment (M30) and plasminogen activator inhibitor-1 (PAI-I) were analyzed as recognized liver inflammatory related biomarkers with specific ELISA kits.

Results: Most measurements related to hepatic damage, inflammation and adiposity status improved at the end of the 6-month nutritional intervention. In addition, ΔFGF-21 shifts showed statistical relationships with changes in ΔM30, ΔGGT and ΔPAI. The reduction of M30 showed significant associations with changes in transaminases. Furthermore, PAI-I changes were associated with ΔM30 and ΔGGT regardless of weight loss. A linear regression model was set up to assess the influence of ΔPAI-I and ΔM30 on the variability of ΔFGF-21 (23.8%) adjusted by weight loss.

Conclusions: These results demonstrated interactions of some liver inflammatory mediators, specifically M30 and PAI-I with FGF-21. Thus, more investigation about FGF-21 is required given that this protein could be a biomarker of the obesity-inflammation-liver process.

Keywords: CK-18; M30-fragment; inflammation; metabolic syndrome; non-alcoholic fatty liver disease; obesity.

Copyright: © 2021 Termedia & Banach.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1

Figure 1

Correlations of changes of fibroblast growth factor 21 (FGF-21) with changes of M30 (CK-18 fragment (A), plasminogen activator inhibitor (PAI-I) (B) and γ-glutamyl transferase (GGT) (C)

Figure 2

Figure 2

Associations between changes of inflammatory related hepatic markers

Figure 3

Figure 3

Changes in fibroblast growth factor 21 (FGF-21) according to the magnitude of changes in M30 and plasminogen activator inhibitor (PAI-I) categorized for median (≥ p50 or < p50). *P < 0.05 was considered statistically significant. +P < 0.05 was considered statistically significant after adjustment for changes in body weight

References

    1. An R, Ji M, Zhang S. Global warming and obesity: a systematic review. Obes Rev. 2018;19:150–63. - PubMed
    1. NCD Risk Factor Collaboration (NCD-RisC) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387:1377–96. - PMC - PubMed
    1. Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13:851–63. - PMC - PubMed
    1. Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol. 2015;13:2062–70. - PubMed
    1. Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943–51. - PMC - PubMed

LinkOut - more resources